Solo therapy with Merck & Co.’s Keytruda is already approved in previously untreated non-small cell lung cancer patients with high levels of the PD-L1 biomarker. Now, thanks to a new FDA green light, it’s allowed in patients with low PD-L1 levels, too. But will doctors actually use it that way?
